tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us
Lexicon Pharmaceuticals (LXRX)
NASDAQ:LXRX
LXRX
Lexicon Pharmaceuticals
Stock Analysis
Analyst Forecasts
Technical Analysis
Options
Chart
Earnings
Dividends
Ownership
Financials
Stock Buybacks
News & Insights
Similar Stocks
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports

Lexicon Pharmaceuticals (LXRX) Stock News & Sentiment

1,314 Followers
Lexicon Pharmaceuticals Welcomes New CEO and COO
PremiumCompany Announcements
Lexicon Pharmaceuticals Welcomes New CEO and COO
14d ago
8K
LXRX
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
PremiumPress Releases
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
14d ago
LXRX
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
PremiumPress Releases
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
1M ago
LXRX
Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
PremiumPress Releases
Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
1M ago
LXRX
Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology
PremiumPress Releases
Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology
1M ago
LXRX
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
PremiumPress Releases
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
1M ago
LXRX
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
PremiumPress Releases
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
2M ago
LXRX
More LXRX News >

LXRX News on the Web

Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
Yahoo Finance
Neutral
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
Zacks
Neutral
FDA Accepts Lexicon's NDA for Type I Diabetes Drug
Yahoo Finance
Neutral
FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug
Zacks
Neutral
Buy Rating Affirmed on Lexicon Pharmaceuticals Amid Promising Sotagliflozin Trials and Upcoming PDUFA Date
TipRanks News
Bullish
Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission
Yahoo Finance
Neutral
New Published Data Highlights Potential Cost-Savings of INPEFA® for Heart Failure
Yahoo Finance
Neutral
Private equity firms account for 48% of Lexicon Pharmaceuticals, Inc.'s ownership, while individual investors account for 33%
Yahoo Finance
Neutral

News Score - Last 7 Days

Neutral
LXRX
Sector Average
Media Buzz
This Week7 articles
Weekly Average3 articles
News Sentiment
This Week100%
Sector Average61%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is LXRX’s Media Buzz Sentiment?
7 articles about LXRX were published this week. In an average week, 3 articles are published.
    What is LXRX’s weekly average amount of articles?
    In an average week, 3 articles about LXRX are published.
      What is LXRX’s News Sentiment?
      100% of articles about LXRX were positive this week, compared to its sector average of 61%.
        Healthcare Stocks that are Trending in the News
        GMEDGlobus Medical
        UNHUnitedHealth
        ISRGIntuitive Surgical
        JNJJohnson & Johnson
        FBIOFortress Biotech
        Showing the stocks with the most bullish news sentiment over the past week

        Get More with TipRanks Premium

        What's Included in PREMIUM?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis
        Subscribe NowSee Plans & Pricing